Skip to main content

FDA Approvals

Payers' Guide, FDA Approvals

Xeljanz XR (Tofacitinib) First Once-Daily Oral JAK Inhibitor Approved for Patients with Rheumatoid Arthritis

Lisa A. Raedler, PhD, RPh

FDA Approvals, Payers' Guide

Innovation Continues to Drive Drug Development, Even as FDA Approvals Drop in 2016

Dalia Buffery, MA, ABD

Novel Hypomethylating Agent Active in Patients with High-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Charles Bankhead

Glasdegib, a Hedgehog Inhibitor, Nearly Doubles Survival in AML or High-Risk MDS

The Hematology Pipeline Features New Immune Therapies, and Targeted Agents

CAR T-Cell Therapy Succeeds in Aggressive Lymphoma

FDA News - December 2016

Plethora of Targeted Agents in the Oncology Pipeline

Payers' Guide, FDA Approvals

Tecentriq (Atezolizumab) First PD-L1 Inhibitor Approved for Patients with Advanced or Metastatic Urothelial Carcinoma

Lisa A. Raedler, PhD, RPh

Biosimilar to Trastuzumab Shows Equivalent Efficacy and Safety

Page 33 of 53
Results 321 - 330 of 522